12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ibrutinib: Interim Phase II data

Interim data from 24 CLL patients >65 years of age and 29 CLL patients with a deletion of chromosome 17p in an open-label, U.S. Phase II trial showed that once-daily 420 mg oral ibrutinib led to an estimated 12-month PFS rate of 94%. At 6 months, 52% of patients had a partial response and 95% of patients experienced a reduction in lymph node size, with a median...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >